Anti-Fibrinolytic Drugs - Asia

Asia

The Anti-Fibrinolytic Drugs market in Asia is expected to witness a significant growth in revenue, with projections indicating a remarkable figure of €3.41bn in 2024.
This market is anticipated to display a steady annual growth rate (CAGR 2024-2029) of 5.37%, ultimately reaching a market volume of €4.43bn by 2029.
It is worth noting that in a global context, United States is projected to generate the highest revenue in this market, amounting to €9,141.00m in 2024.
In Asia, Japan is leading the market for anti-fibrinolytic drugs with its advanced research and development capabilities.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Anti-Fibrinolytic Drugs in Asia is on the rise due to various factors that have influenced the market.

Customer preferences: Anti-Fibrinolytic Drugs are commonly used in Asia to treat excessive bleeding during surgeries or trauma. The rise in the number of surgeries and trauma cases has increased the demand for these drugs. Additionally, the increasing prevalence of hemophilia and other blood clotting disorders has also contributed to the growth of the market.

Trends in the market: Japan and China are the largest markets for Anti-Fibrinolytic Drugs in Asia. In Japan, the market is driven by the increasing number of surgeries being performed, especially in the aging population. The market in China is growing due to the increasing awareness about the benefits of these drugs and the rising number of trauma cases. India is also a significant market due to the high prevalence of hemophilia.

Local special circumstances: In Japan, the aging population is a significant factor driving the growth of the Anti-Fibrinolytic Drugs market. The elderly population is more prone to diseases and requires more surgeries, which has increased the demand for these drugs. In China, the government's efforts to improve healthcare infrastructure and increase access to medical facilities have contributed to the growth of the market. In India, the lack of awareness about hemophilia and other blood clotting disorders is a major challenge for the market.

Underlying macroeconomic factors: The economic growth in Asia has led to an increase in healthcare spending, which has benefited the Anti-Fibrinolytic Drugs market. Additionally, the rise in disposable income has made healthcare more affordable for people, leading to an increase in demand for these drugs. The increasing focus on research and development activities in the pharmaceutical sector has also led to the development of new and advanced Anti-Fibrinolytic Drugs, which has further boosted the market growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.